< Nouvelles

Postdoctoral training in personalized health

Pr Helen-Maria Vasiliadis is offering a 2-year postdoctoral training in personalized health

The candidate will be part of the research team, will be supervised by a senior FRQS scholar with great experience in the field and will be supported by a senior statistician.

 

 

Study description

Titled « Anxio-depressive symptoms and treatment adherence trajectories associated with clinical outcomes and quality of life in a cohort of community sample of older adults with chronic disorders ». The study will focus on predicting persistence, recurrence or relapse of common mental disorders so that clinical interventions can be tailored to patient profiles for improved outcomes.

The study received a CIHR Personalized Health Catalyst Grant and covers psychiatric epidemiology : life course – health trajectories – mental health disorders, suicidal ideation, cognition and related factors. It encompasses pharmacoepidemiology: medication adherence trajectories, psychotropic drug use and medications for chronic diseases (diabetes, hypertension). There is also opportunity to carry out pharmaco-economics related research assessing the costs and benefits of integrating personalized health care into primary care for older adults.

Eligibility

This 2-year postdoctoral training will be granted to a PhD in a field related to health sciences or medecine with interests in epidemiology, pharmacoepidemiology and pharmacoeconomics.  The candidate must have statistical expertise and be fluent in English, written and oral.

For submissions or information

Please send your resume, a presentation letter and your most recent official transcript to  helen-maria.vasiliadis@usherbrooke.ca.

 


About Helen-Maria Vasiliadis

Helen-Maria Vasiliadis is a regular researcher at the CR-HCLM and professor at the département des sciences de la santé communautaire de l’UdeS. Her research program targets determinants of mental health service use (access and equity); cost analysis and health service efficacy for psychiatric patients; quality of life as well as economic program evaluation.